

## We Claim:

1. (S)-2-{[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydrofuran-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester having the following structure:

or a stereoisomer thereof.

The compound as claimed in claim 1 wherein the stereoisomer is (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate having following structure:

The compound as claimed in claim 1 wherein the stereoisomer is (S)-isopropyl 2-(((R)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate having following structure:

- 4. A composition comprising the compound as claimed in any of the claims 1 to 3, and a pharmaceutically acceptable medium.
- 5. A process for preparing the compound or a stereoisomer thereof as claimed in claim 1, said process comprising:

reacting a compound 4" with a nucleoside analog 5'

wherein X' is a leaving group.

Dated this the 20<sup>th</sup> day of October, 2009.

AMRISH TIWARI
OF K&S PARTNERS
ATTORNEY FOR THE APPLICANT
IN-PA/1202